



BUILDING TOMORROW'S BREAKTHROUGHS



ABOUT US

Based in Zurich, Switzerland, Molecular Partners (SIX: MOLN) is a clinical-stage biotechnology company working to deliver effective and safe new therapies to transform the lives of people with cancer and other serious diseases. We aim to move the needle of medicine by repeatedly delivering innovative DARPin® therapies in oncology.

DARPin® Features

- High affinity and specificity
- DARPin® module: 1 domain, 1 specificity, 15 kDa
- DARPin® modules are readily combined into a multi-DARPin® candidate (up to 6 modules with a variety of linkers)
- Novel therapeutic design space becomes accessible




OUR APPROACH

Our DARPin® technology opens new therapeutic design space, offers a fast cycle of innovation, and has been validated through preclinical and clinical studies. We rapidly test ideas and develop clinical DARPin® candidates to show patient benefit — alone and together with our partners. Our DARPin® technology is protected by multiple layers of patents.

DARPin® APPROACHES IN ONCOLOGY


We are applying our DARPin® platform to create novel cancer therapies that can address many of the challenges of present-day cancer treatment.





PIPELINE

Our DARPin® engine is the source of our future product candidates and allows for novel therapeutic design.



AMD: age-related macular degeneration; DME: diabetic macular edema; NSCLC: non-small cell lung cancer

1,800+

DARPin® candidates have been tested in over 1,800 patients worldwide in ophthalmology and oncology.

PRODUCTS

MP0250, Multiple myeloma and EGFR-mutated non small-cell lung cancer

The company's lead oncology program MP0250 is designed to block both the VEGF and HGF pathways and has the potential to overcome adaptive tumor resistance.

MP0274, HER2-positive cancers

MP0274 is a DARPin® therapeutic candidate designed to bind two different epitopes on HER2 on tumor cells, resulting in cancer cell death through apoptosis.

MP0310, Immuno-oncology

MP0310 is the first product candidate in the company's DARPin® immuno-oncology pipeline. It is designed to activate immune cells preferentially in the tumor potentially delivering greater efficacy with fewer side effects.

Abicipar, Ophthalmology

Abicipar is the company's most advanced DARPin® therapeutic candidate, under investigation for the treatment of wet AMD and DME. Based on the phase 3 trials, Abicipar has the potential to be the first anti-VEGF for wet AMD patients with a fixed 12 week dosing regimen. Molecular Partners exclusively licensed Abicipar to Allergan in May 2011 on a worldwide basis in the field of ophthalmology. Additional DARPin® candidates in ophthalmology are in preclinical development with Allergan.



Wagistrasse 14
8952 Zurich-Schlieren
Switzerland

Phone: +41 44 755 77 00
investors@molecularparters.com